Brentuximab vedotin: Anti-CD30 antibody-drug conjugate oncolytic

Drugs of the Future

Volumn 35, Issue 10, 2010, Pages 797-801

  Copeland, A ^a   Younes, A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; SGN 30;

ACUTE KIDNEY FAILURE; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANTINEOPLASTIC ACTIVITY; CANCER RELAPSE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG FEVER; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; IC 50; LARGE CELL LYMPHOMA; LYMPHOMA; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATITIS; RETREATMENT; REVIEW; SENSORY NEUROPATHY; T CELL LYMPHOMA; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 79956195521     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.010.1524349     Document Type: Review

References (30)

1. Doronina, S.O., Toki, B.E., Torgov, M.Y. et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003, 21(7): 778-84. (Pubitemid 36791396)
2. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M.J. Cancer Statistics, 2009. CA Cancer J Clin 2009, 59(4): 225-49.
3. Savage, K.J., Harris, N.L., Vose, J.M. et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood 2008, 111(12): 5496-504.
4. Altekruse, S.F., Kosary, C.L., Krapcho, M. et al. (Eds). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
5. Horning, S.J., Fanale, M., De Vos, S. Defining a population of Hodgkin lymphoma patients for novel therapeutics: An international effort. Ann Oncol 2008, 20: 118.
6. Gruss, H.J., Herrmann, F. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells. Leuk Lymphoma 1996, 20(5-6): 397-409. (Pubitemid 26096045)
7. Pizzolo, G., Vinante, F., Morosato, L. et al. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS 1994, 8(6): 741-5. (Pubitemid 24163414)
8. Fattovich, G., Vinante, F., Giustina, G., Morosato, L., Alberti, A., Ruol, A., Pizzolo, G. Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol 1996, 103(1): 105-10. (Pubitemid 26027380)
9. Giacomelli, R., Cipriani, P., Lattanzio, R. et al. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol 1997, 108(1): 42-6. (Pubitemid 27140328)
10. Hsu, P.L., Hsu, S.M. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: Distinction between Hodgkin's disease and anaplastic large cell lymphoma. Lab Invest 2000, 80(7): 1111-9.
11. Wahl, A.F., Klussman, K., Thompson, J.D. et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002, 62(13): 3736-42. (Pubitemid 34728855)
12. Bartlett, N.L., Younes, A., Carabasi, M.H. et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008, 111(4): 1848-54. (Pubitemid 351451492)
13. Forero-Torres, A., Leonard, J.P., Younes, A. et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009, 146(2): 171-9.
14. Blum, K.A., Jung, S.H., Johnson, J.L. et al. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. Ann Oncol 2010, Epub ahead of print.
15. Maeda, N., Muta, H., Oflazoglu, E., Yoshikai, Y. Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo. Cancer Sci 2010, 101(1): 224-30.
16. th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 1470.
17. Okeley, N.M., Miyamoto, J.B., Zhang, X. et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010, 16(3): 888-97.
18. Sutherland, M.S.K., Sanderson, R.J., Gordon, K.A. et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006, 281(15): 10540-7. (Pubitemid 43864594)
19. Francisco, J.A., Cerveny, C.G., Meyer, D.L. et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102(4): 1458-65. (Pubitemid 36988057)
20. Oflazoglu, E., Kissler, K.M., Sievers, E.L., Grewal, I.S., Gerber, H.-P. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008, 142(1): 69-73. (Pubitemid 351783148)
21. Hamblett, K.J., Senter, P.D., Chace, D.F. et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004, 10(20): 7063-70. (Pubitemid 39383058)
22. th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 1006.
23. st Annu Meet Am Soc Hematol (Dec 5-8, New Orleans) 2009] 2009, 114(22): Abst 2731.
24. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 8062.
25. Ansell, S., Horwitz, S., Engert, A. et al. Increased doses of an anti-CD30 antibody, MDX-060, results in prolonged progression free survival in subjects with CD30 positive lymphoma. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst 5525.
26. Thertulien, R., Frankel, A., Evens, A. A phase I, open-label, dose-escalation, multidose study of MDX-1401 (defucosylated human antiCD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed Hodgkin's lymphoma. Proc Am Assoc Cancer Res (AACR) 2009, 50: Abst 1227.
27. th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 5012.
28. A pivotal open-label trial of SGN-35 for Hodgkin lymphoma (NCT00848926). ClinicalTrials.gov Web site, September 22, 2010.
29. A phase 1 study of brentuximab vedotin combined with ABVD for Hodgkin lymphoma (NCT01060904). ClinicalTrials.gov Web site, September 22, 2010.
30. A phase 3 study of brentuximab vedotin (SGN-35) in patients at high risk of residual Hodgkin lymphoma following stem cell transplant (The AETHERA Trial) (NCT01100502). ClinicalTrials.gov Web site, September 22, 2010.